



## **Announcing the Sale of Arysta LifeScience to UPL and a New Chapter for Platform**



**July 20, 2018**

Please note that in this presentation, we may discuss events or results that have not yet occurred or been realized, commonly referred to as forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of the Company. Such discussion and statements will often contain words such as “expect,” “anticipate,” “project,” “will,” “should,” “believe,” “intend,” “plan,” “estimate,” “predict,” “seek,” “continue,” “outlook,” “pro forma,” “may,” “might,” “should,” “can have,” “likely,” “potential,” “target,” and variation of such words and similar expressions, and relate in this presentation, without limitation, to statements, beliefs, projections and expectations regarding the proposed sale of the Company’s Agricultural Solutions segment; the timing for completion of this transaction; the ability of the Company to close the transaction; use of proceeds; key terms and anticipated benefits of the transaction and its impact on the Company’s business and financial results, including its go-forward vision and strategy; pro forma adjusted EBITDA and go-forward net leverage target range; capital allocation; share buybacks; expected run-rate cost savings; margin profile; free cash flow and use of free cash flow and excess liquidity; the Company’s capex, tax rate, net debt to adjusted EBITDA ratio; the Company’s new target capital structure and financial outlook, including long term average target and pro forma 2018 expectations for organic growth, adjusted EBITDA, net capex, cash interest and cash taxes; the outlook for the Company’s markets and the demand for its products. These projections and statements are based on management’s estimates, assumptions and expectations with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those expressed or implied in the forward-looking statements if one or more of the underlying estimates, assumptions or expectations prove to be inaccurate or are unrealized. Important factors that could cause actual results to differ materially from those suggested by the forward-looking statements include, but are not limited to, the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreement to sell Agricultural Solutions; the ability of the purchaser to obtain the proceeds of the debt and equity financings necessary to satisfy the purchase price; the risk that the necessary regulatory approvals may not be obtained or may be delayed or obtained subject to conditions that are not anticipated; the risk that the transaction will not be consummated in a timely manner; the risk that the Company will experience unanticipated delays or difficulties and transaction costs in consummating the transaction; the risk that any of the closing conditions to the transaction may not be satisfied in a timely manner or at all; the risk related to disruption from the transaction and the related diverting of management’s attention making it more difficult to maintain business and operational relationships; the failure to realize the benefits expected from the transaction or other related strategic initiatives; the impact of the transaction on the Company’s share price and market volatility; the effect of the announcement of the transaction on the ability of the Company to retain customers and suppliers, retain or hire key personnel, and maintain relationships with customers, suppliers and lenders; the effect of the transaction or the announcement and completion of related transactions on the Company’s operating results and businesses generally; the impact of the U.S. Tax Cuts and Jobs Act of 2017 (the “Tax Reform”) on the transaction and the Company’s businesses; the impact of any future acquisitions or additional divestitures, restructurings, refinancings, and other unusual items, including the Company’s ability to raise or retire debt or equity and to integrate and obtain the anticipated benefits, results and/or synergies from these items or other related strategic initiatives; and the possibility of more attractive strategic options arising in the future. Forward-looking statements regarding the anticipated impact of the Tax Reform on the Company’s businesses consist of preliminary estimates, which are based on currently available information as well as management’s current interpretations, assumptions and expectations relating to the Tax Reform, and subject to change, possibly materially, as the Company completes its analysis. Additional information concerning these and other factors that could cause the Company’s actual results to vary is, or will be, included in the Company’s periodic and other reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Industry, market and competitive position data described in this presentation were obtained from the Company’s own internal estimates and research, as well as from industry and general publications and research, surveys and studies conducted by third parties. While the Company believes its internal estimates and research are reliable and the market definitions are appropriate, such estimates, research and definitions have not been verified by any independent source. You are cautioned not to place undue reliance on this data.

# NON-GAAP INFORMATION



To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States ("GAAP"), the Company uses the following non-GAAP financial measures: EBITDA and adjusted EBITDA, adjusted EBITDA margin, adjusted levered free cash flow, free cash flow, LTM adjusted EBITDA, LTM net leverage, net debt to adjusted EBITDA ratio, net working capital, and organic sales growth. The Company also evaluates and presents its results of operations on a constant currency basis.

The reconciliations of these non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP can be found in the footnotes and appendix of this presentation. The Company only provides adjusted EBITDA guidance and organic sales growth expectations on a non-GAAP basis and does not provide reconciliations of such forward-looking non-GAAP measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including adjustments that could be made for restructurings, refinancings, divestitures, integration and acquisition-related expenses, share-based compensation amounts, nonrecurring, unusual or unanticipated charges, expenses or gains, adjustments to inventory and other charges reflected in the reconciliation of historic numbers, the amount of which, based on historical experience, could be significant.

Management internally reviews each of these non-GAAP measures to evaluate performance on a comparative period-to-period basis in terms of absolute performance, trends and expected future performance with respect to the Company's business, and believes that these non-GAAP measures provide investors with an additional perspective on trends and underlying operating results on a period-to-period comparable basis. Platform also believes that investors find this information helpful in understanding the ongoing performance of its operations separate from items that may have a disproportionate positive or negative impact on Platform's financial results in any particular period or are considered to be costs associated with our capital structure. These non-GAAP financial measures, however, have limitations as analytical tools, and should not be considered in isolation from, a substitute for, or superior to, the related financial information that the Company reports in accordance with GAAP. The principal limitations of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company's financial statements, and may not be completely comparable to similarly titled measures of other companies due to potential differences in calculation methods. In addition, these measures are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded or included in determining these non-GAAP financial measures. Investors are encouraged to review the reconciliations of these non-GAAP financial measures to their most comparable GAAP financial measures included herein, and not to rely on any single financial measure to evaluate Platform's businesses.

In addition, this presentation contains "pro forma" information, including pro forma adjusted EBITDA, pro forma adjusted EBITDA guidance, pro forma cash generation, pro forma LTM adjusted EBITDA and pro forma annualized adjusted EBITDA. This pro forma information excludes the results of the Arysta business by assuming a transaction closing on January 1, 2018 and includes the full benefit of approximately \$25 million of estimated run-rate cost savings expected to be delivered in 2019. This presentation also contains unaudited "comparable" financial information which assumes full period contribution of Alent plc, and the Electronic Chemicals and Photomasks businesses of OM Group, Inc. acquired in 2015; and OMG Electronic Chemicals (M) Sdn Bhd acquired in 2016. This combined and pro forma information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had the Company's acquisitions or closing of the transaction been completed as of the dates indicated, or that may be achieved in the future. The pro forma information may also not be comparable to the pro forma information required to be provided in connection with the transaction closing. Historical financial results and information relating to the Company's acquired businesses were derived from public filings, when applicable, and/or information provided by management of these businesses prior to their acquisitions. Although we believe it is reliable, this information has not been verified, internally or independently. In addition, financial information for some of these acquired businesses was historically prepared in accordance with non-GAAP accounting methods, and may or may not be comparable to the Company's financial statements. Consequently, there is no assurance that the financial results and information for these legacy businesses are accurate or complete, or representative in any way of the Company's actual or future results as a consolidated company.

Please see the footnotes and appendix to this presentation for more detailed descriptions of the non-GAAP financial measures used by the Company, including the adjustments reflected in each of them and the reason why we believe such non-GAAP measures are useful to investors.

**Platform announced a definitive agreement to sell its Agricultural Solutions segment, Arysta LifeScience, to UPL Limited at a value of \$4.2 billion in cash, subject to customary adjustments**

- Transaction would conclude the previously announced separation of Platform's businesses
- Closing expected in late 2018 or early 2019, subject to customary closing conditions and regulatory approvals
- Combination is expected to create one of the largest crop protection and formulation-technology companies in the world

**For Platform, this transformational transaction marks the beginning of a new chapter**

- Effective at close, Platform plans to change its name to Element Solutions Inc
- Reorganizing to a "one-company structure"
- Compelling go-forward portfolio and strategy to compound value for shareholders

**Element Solutions is expected to have an annualized pro forma 2018 Adj. EBITDA<sup>1\*</sup> of \$450 million - \$470 million and a pro forma LTM net leverage of less than 2.5x**


- Annualized pro forma Adj. EBITDA<sup>1\*</sup> based on 2018 Adj. EBITDA\* guidance of \$425 million to \$445 million, plus ~\$25 million of estimated run-rate cost savings from a reorganization expected to be realized in 2019
- Expected net debt of less than \$1 billion
- Platform's board of directors has approved a share buy-back program of up to \$750 million, conditioned on the closing of the sale of Arysta
- Go-forward net leverage target range of 3.0x to 3.5x Adj. EBITDA\*

**This transaction represents an inflection point and transformational opportunity for Platform to accelerate its separation and position itself for long-term value creation**

\* The financial measures, on this slide and subsequent slides, are not in accordance with GAAP. For definitions of these non-GAAP measures, discussions of adjustments and reconciliations, please refer to the appendix of this presentation

1. Annualized pro forma adj. EBITDA assumes a transaction completed on January 1, 2018 and ~\$25 million of annualized estimated run-rate cost savings from a reorganization expected to be realized in 2019

# TRANSACTION OVERVIEW

- 
**Combination is expected to form one of the largest crop protection and formulation-technology companies in the world with an integrated, efficient supply chain, formulation expertise and global distribution capability**
  - Complementarity of these two businesses will deliver meaningful value to growers, distributors, suppliers and other partners

<b>Acquirer</b>	<ul style="list-style-type: none"> <li>▪ UPL Corporation Ltd., a wholly-owned subsidiary of UPL Limited</li> </ul>
<b>Valuation</b>	<ul style="list-style-type: none"> <li>▪ Enterprise value of 4.2 billion               <ul style="list-style-type: none"> <li>○ Subject to customary closing adjustments for working capital and other items</li> </ul> </li> </ul>
<b>Consideration</b>	<ul style="list-style-type: none"> <li>▪ Cash transaction for 100% ownership of Arysta LifeScience Inc.</li> </ul>
<b>Key Terms</b>	<ul style="list-style-type: none"> <li>▪ Valuation assumes debt-free and cash-free transaction</li> <li>▪ Committed financing for entire purchase price</li> <li>▪ No other material conditions or contingencies</li> </ul>
<b>Timing</b>	<ul style="list-style-type: none"> <li>▪ Closing expected in late 2018 or early 2019               <ul style="list-style-type: none"> <li>○ Subject to customary closing conditions and regulatory approvals</li> </ul> </li> </ul>

\* See Non-GAAP footnote on p.4

# PLATFORM'S NEW CHAPTER

# NEW CORPORATE IDENTITY – ELEMENT SOLUTIONS



- In connection with this transformational transaction, Platform announced a plan to change its name to Element Solutions Inc, reflecting the creation of a new identity and strategy
- Effective at closing, Platform to become Element Solutions Inc and to trade under the ticker symbol “NYSE:ESI”
- Brands, trade names and ‘go-to market’ of existing businesses will remain unchanged



element  
solutions

element: Our products are the unseen, small yet completely integral components to the functioning of products all around us

solutions: Our products, generally aqueous, are formulated, not synthesized; we do not make molecules; we formulate and offer critical solutions for our customers



## Diversified specialty chemicals business with market leading positions across multiple attractive end markets

- End-market breadth allows for stability through cycles, while specific high-growth end-market exposures allow for attractive growth profile




## Integral products that are integrated into customer supply chain

- High-margin businesses with low capital requirements translating to stable, high-cash flow producing portfolio

## Strong technical barriers to entry

## Fragmented end-markets create room for further consolidation and attractive consolidation opportunities

### Leading Businesses Across Diverse Industries with Shared End-Markets and Management

	 <b>MacDermid Enthone</b> INDUSTRIAL SOLUTIONS	 <b>MacDermid Enthone</b> ELECTRONIC SOLUTIONS	 <b>alpha Q</b> ASSEMBLY SOLUTIONS <small>A MacDermid Performance Solutions Business</small>	 <b>MacDermid</b> GRAPHICS SOLUTIONS	 <b>MacDermid</b> OFFSHORE SOLUTIONS
Products	<ul style="list-style-type: none"> <li>Corrosion resistance</li> <li>Decorative finishes</li> <li>Plating-on-plastic</li> </ul>	<ul style="list-style-type: none"> <li>Circuit board metallization</li> <li>Through-hole plating and surface finishing</li> </ul>	<ul style="list-style-type: none"> <li>Solder paste</li> <li>Solder spheres</li> <li>Pre-forms</li> </ul>	<ul style="list-style-type: none"> <li>Flexographic printing plates</li> </ul>	<ul style="list-style-type: none"> <li>Temperature and pressure resistant hydraulic fluids</li> <li>Blow-out prevention fluids</li> </ul>
Markets	<ul style="list-style-type: none"> <li>Automotive</li> <li>Construction</li> <li>Consumer electronics</li> <li>Aerospace</li> <li>Oil and gas</li> </ul>	<ul style="list-style-type: none"> <li>Mobile devices</li> <li>Automotive electronics</li> <li>Telecom infrastructure</li> <li>Servers and storage</li> </ul>	<ul style="list-style-type: none"> <li>Consumer electronics</li> <li>Automotive</li> <li>Medical</li> <li>Aerospace</li> </ul>	<ul style="list-style-type: none"> <li>Consumer packaged goods</li> </ul>	<ul style="list-style-type: none"> <li>Oil and gas production</li> </ul>

### Long-term focus on compounding free cash flow through efficient operations and prudent capital allocation

## End-Market Focus

- Niche, electronics, industrial and energy end-markets
- Emphasis on growing in semi-conductors and automation-related technologies

## Organic Growth

- Organic growth in line with GDP

## Margin Expansion

- Strong incremental Adj. EBITDA margins on new sales; margin expansion expected as the business grows

## Capital Allocation

- Measured acquisitions within existing end-markets or adjacencies with a preference for buying back stock if ESI stock price is trading at a discount compared to acquisition pipeline valuation

## Leverage

- Net leverage target range of 3.0x – 3.5x Adj. EBITDA\*

- **Best-in-class returns on capital and cash-flow generation**
- **Balanced strategy of operational excellence and capital allocation**
- **Long runway to continue to compound value through organic growth and sensible capital allocation**

\* See Non-GAAP footnote on p.4


# FINANCIAL REVIEW

# ESI – STRONG FINANCIAL PROFILE

Element Solutions' portfolio has delivered strong organic growth and positive incremental margins, while maintaining an "Asset-Lite" and efficient business model

## ESI – Net Sales

(\$ millions)




Growth Rates (%)

Comparable/Reported	(1%)	6%	7%
Organic*	1%	4%	4%

## ESI – Adj. EBITDA\*


(\$ millions)



Growth Rates (%)

Comparable/Reported	5%	8%
Organic*	9%	8%

*Pro Forma*




(\$ millions)	Platform LTM Adj. EBITDA (3/31/2018)	Δ	Element PF LTM Adj. EBITDA (3/31/2018)
Performance Solutions	\$474	\$-	\$474
Agricultural Solutions	424	(424)	-
Corporate Costs	(63)	-	(63)
Est. Savings from Reorganization	-	25	25
<b>Total</b>	<b>\$835</b>		<b>\$436</b>

*~\$25+ million estimated run-rate cost savings expected to be realized in 2019*

## Estimated Closing Net Debt

(\$ millions)



Note: Totals may not sum due to rounding

\* See Non-GAAP footnote on p.4

1. Segment adj. EBITDA includes historical corporate cost allocations of \$24 million, \$33 million and \$31 million in 2015, 2016 and 2017, respectively

2. Pro forma LTM adj. EBITDA and annualized pro forma adj. EBITDA (assuming a transaction completed on January 1, 2018) assumes ~\$25 million of annualized estimated run-rate cost savings from a reorganization expected to be realized in 2019

# ESI – STRONG FREE CASH FLOW GENERATION

## Adjusted Levered Free Cash Flow\*

(\$ millions)

	PAH		ESI	
	2016	2017	2016	2017
<b>Net Sales</b>	<b>\$3,586</b>	<b>\$3,776</b>	<b>\$1,770</b>	<b>\$1,879</b>
% growth		5%		6%
<b>Adj. EBITDA*</b>	<b>\$769</b>	<b>\$821</b>	<b>\$401<sup>1</sup></b>	<b>433<sup>1</sup></b>
% margin	21.5%	21.7%	22.7%	23.0%
Less: Net CapEx <sup>2*</sup>	(72)	(82)	(25)	(14)
Less: Change in Net Working Capital <sup>3*</sup>	(16)	(58)	(27)	(45)
Less: Cash Taxes	(121)	(145)	(62)	(74)
Less: Cash Interest	(360)	(323)	(65) <sup>4</sup>	(65) <sup>4</sup>
<b>Adj. Levered Free Cash Flow*</b>	<b>\$200</b>	<b>\$213</b>	<b>\$222</b>	<b>\$236</b>
% of sales	5.6%	5.6%	12.5%	12.6%

- Element Solutions would have a higher margin profile vs. Platform and a more efficient cash flow conversion
- Transaction expected to increase overall free cash flow
- Expected net capex of less than 2% of sales going forward and lower working capital intensity and volatility than Platform
- Transaction is expected to significantly improve the tax rate
  - Expect initial tax rate in mid to high-20s
- Free cash flow would be used to further de-lever, return capital to shareholders and for measured inorganic investments

**The sale of Agricultural Solutions and Element Solutions' new capital structure are expected to be accretive to free cash flow and to reduce capital intensity and tax rates, which should significantly improve cash flow conversion**

**Based on illustrative capital structure**

Note: Totals may not sum due to rounding

\* See Non-GAAP footnote on p.4

1. Segment adj. EBITDA includes historical corporate cost allocations of \$33 million and \$31 million in 2016 and 2017, respectively, and does not reflect the announced ~\$25 million annualized estimated run-rate cost savings expected to be realized in 2019

2. Net capex is defined as capital expenditures plus investments in registrations of products less the impact of proceeds from disposal of property, plant and equipment

3. Net working capital is defined as accounts receivable plus inventories less accounts payable

4. Illustrative interest expense for Element assuming \$300M revolver with 0.5% commitment fee, \$400M term loans at L+2.00%, and \$800M in 5.875% senior notes

- Element Solutions is committed to using free cash flow and excess liquidity prudently to drive shareholder value

## Contemplated Use of Pro Forma Free Cash Flow and Purchase Price Proceeds

Debt pay-down

Share buybacks<sup>1</sup>

Measured acquisitions within existing and adjacent markets

Conservative go-forward net leverage target range of 3.0x to 3.5x Adj. EBITDA\*

\* See Non-GAAP footnote on p.4

1. Platform's board has approved a share buy-back program of up to \$750 million conditioned on the closing of the sale of Arysta

 **Best-in-class cash flow with conservative leverage**

	Long Term Average Target	Pro Forma 2018 Expectations
<b>Organic Growth Rate*</b>	~3 – 4%	~4%
<b>Adjusted EBITDA*</b>	23% + margin	\$450 million - \$470 million on an annualized pro forma basis <sup>1</sup>
<b>Net Capex<sup>2*</sup></b>	< 2% of sales	~\$30 million (< 2% of sales)
<b>Cash Interest</b>	Leverage < 3.5x	~\$60-70 million
<b>Cash Taxes</b>	% in mid to high 20s	~\$80 million - \$85 million

**2018 pro forma cash generation of up to \$300 million on an annualized basis<sup>3</sup>**

\* See Non-GAAP footnote on p.4

1. Annualized pro forma adj. EBITDA assumes a transaction completed on January 1, 2018 and ~\$25 million of annualized estimated run-rate cost savings expected to be realized in 2019

2. Net capex is defined as capital expenditures plus investments in registrations of products less the impact of proceeds from disposal of property, plant and equipment

3. Cash generation defined as adjusted EBITDA less net capex, cash interest, cash taxes and an assumed net working capital investment of < \$25 million

**Execution: Build on Operating Momentum and Continue to Drive Above Market Revenue Growth**

**Manage Cost and Drive Margin Expansion through Synergies and Continuous Improvement**

**Generate Free Cash Flow and Reduce Leverage**

**Ensure a Successful Separation to Maximize Shareholder Value**



# APPENDIX

# PLATFORM CURRENT CAPITAL STRUCTURE



\$ millions			
Instrument	Maturity	Coupon	3/31/2018
Corporate Revolver	6/7/2020		\$52
Term Loan B6 - USD <sup>1,2</sup>	6/7/2023	L + 300	1,135
Term Loan B7 - USD <sup>1</sup>	6/7/2020	L + 250	630
Term Loan C5 - EUR <sup>1,2</sup>	6/7/2023	E + 275	739
Term Loan C6 - EUR <sup>1</sup>	6/7/2020	E + 250	719
Other Secured Debt			19
<b>Total First Lien Debt</b>			<b>\$3,295</b>
6.5% Senior Notes due 2022	2/1/2022	6.500%	\$1,100
6.0% Senior Notes due 2023 (Euro)	2/1/2023	6.000%	431
5.875% Senior Notes due 2025	12/1/2025	5.875%	800
Other Unsecured Debt			51
<b>Total Unsecured Debt</b>			<b>\$2,382</b>
<b>Total Debt</b>			<b>\$5,677</b>
Cash Balance at 3/31/18			\$413
<b>Net Debt</b>			<b>\$5,264</b>
Adjusted Shares Outstanding <sup>3</sup>			302
Market Capitalization <sup>4</sup>			<b>\$2,908</b>
<b>Total Capitalization</b>			<b>\$8,172</b>

Note: Totals may not sum due to rounding

1. Platform swapped certain of its floating term loans to fixed rate including \$1.13 billion of its USD tranches and €278 million of its Euro tranches. At March 31, 2018, approximately 33% of debt was floating and 67% was fixed
2. These term loans mature on June 7, 2023, provided that the Company prepays, redeems or otherwise retires and/or refinances in full its 6.50% USD Senior Notes due 2022, as permitted under its Amended and Restated Credit Agreement, on or prior to November 2, 2021, otherwise the maturity reverts to November 2, 2021
3. See p.19 for reconciliation to Adjusted Share Counts
4. Based on Platform's closing price of \$9.63 at March 29, 2018, the last trading day of Q1 2018

# RECONCILIATION TO ADJUSTED SHARE COUNTS

<i>(amounts in millions)</i>		Q1 2018
<b>Basic outstanding shares</b>		<b>288</b>
Number of shares issuable upon conversion of PDH Common Stock		4
Number of shares issuable upon conversion of Series A Preferred Stock		2
Number of shares issuable upon vesting and exercise of Stock Options		1
Number of shares issuable upon vesting of granted Equity Awards		7
<b>Adjusted shares</b>		<b>302</b>

# NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS RECONCILIATION TO ADJ. EBITDA



(\$ millions)	Q1 2018	Q1 2017
<b>Net income (loss) attributable to common stockholders</b>	<b>\$37</b>	<b>\$(24)</b>
<b>Add (subtract):</b>		
Net income attributable to the non-controlling interests	1	1
Income tax expense	65	19
Interest expense, net	78	89
Depreciation expense	20	17
Amortization expense	72	69
<b>EBITDA</b>	<b>\$273</b>	<b>\$170</b>
<b>Adjustments to reconcile to Adjusted EBITDA:</b>		
Restructuring expense	3	2
Acquisition and integration costs	1	4
Non-cash change in fair value of contingent consideration	1	1
Foreign exchange (gain) loss on foreign denominated external and internal long-term debt	(56)	12
Nonrecourse factoring costs	1	1
Debt refinancing costs	—	1
Costs related to Proposed Separation	3	0
Gain on sale of equity investment	(11)	—
Other, net	(7)	2
<b>Adjusted EBITDA</b>	<b>\$207</b>	<b>\$193</b>

Note: Totals may not sum due to rounding

# NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS RECONCILIATION TO ADJ. EBITDA



(\$ millions)	FY 2017	FY 2016	FY 2015
<b>Net loss attributable to common stockholders</b>	<b>\$(296)</b>	<b>\$(41)</b>	<b>\$(309)</b>
<b>Add (subtract):</b>			
Gain on amendment of Series B Convertible Preferred Stock	—	(33)	—
Net income (loss) attributable to the non-controlling interests	1	(3)	4
Income tax expense	7	29	75
Interest expense, net	342	376	214
Depreciation expense	78	75	49
Amortization expense	276	267	202
<b>EBITDA</b>	<b>\$407</b>	<b>\$670</b>	<b>\$236</b>
<i>Adjustments to reconcile to Adjusted EBITDA:</i>			
Restructuring expense	31	31	25
Amortization of inventory step-up	—	12	77
Acquisition and integration costs	5	33	122
Non-cash change in fair value contingent consideration	3	5	7
Legal settlements	(11)	(3)	(16)
Foreign exchange loss on foreign denominated external and internal long-term debt	103	34	46
Fair value loss on foreign exchange forward contract	—	—	74
Goodwill impairment	160	47	—
Gain on settlement agreement related to Series B Convertible Preferred Stock	—	(103)	—
Non-cash change in fair value of preferred stock redemption liability	—	5	—
Debt refinancing costs	83	20	—
Costs related to Proposed Separation	12	—	—
Pension plan settlement and curtailment	11	2	—
Other, net	18	17	(3)
<b>Adjusted EBITDA</b>	<b>\$821</b>	<b>\$769</b>	<b>\$568</b>

Note: Totals may not sum due to rounding

# MPS – COMPARABLE SALES RECONCILIATION

(\$ millions)	2016	2015	YoY%
<b>Net Sales</b>	<b>\$1,770</b>	<b>\$801</b>	<b>121%</b>
<u>Acquisitions:</u>			
Alent		847	
OM		142	
<b>Comparable Sales</b>	<b>\$1,770</b>	<b>\$1,791</b>	<b>(1)%</b>

# MPS – EBITDA RECONCILIATION

(\$ millions)	2017	2016	YoY%
<b>Adj. EBITDA ex-corp cost</b>	<b>\$464</b>	<b>\$434</b>	<b>7%</b>
Corporate allocations	(31)	(33)	
<b>Adj. EBITDA</b>	<b>\$433</b>	<b>\$401</b>	<b>8%</b>
Foreign exchange translation	1		
<b>Constant Currency</b>	<b>\$434</b>	<b>\$401</b>	<b>8%</b>

(\$ millions)	2016	2015	YoY%
<b>Adj. EBITDA ex-corp cost</b>	<b>\$434</b>	<b>\$236</b>	<b>84%</b>
Acquisitions:			
Alent		143	
OM		28	
<b>Comparable Adj. EBITDA ex-corp cost</b>	<b>\$434</b>	<b>\$407</b>	<b>7%</b>
Corporate allocations	(33)	(24)	
<b>Comparable Adj. EBITDA</b>	<b>\$401</b>	<b>\$384</b>	<b>5%</b>
Foreign exchange translation	15		
<b>Comparable Constant Currency</b>	<b>\$417</b>	<b>\$384</b>	<b>9%</b>

Note: Totals may not sum due to rounding

# QUARTERLY RESULTS OVERVIEW

(\$ millions)	2017				2018
	Q1	Q2	Q3	Q4	Q1
<b><u>Net Sales</u></b>					
Performance Solutions	\$447	\$462	\$481	\$489	\$492
Agricultural Solutions	415	479	424	580	472
<b>Total Net Sales</b>	<b>\$862</b>	<b>\$941</b>	<b>\$904</b>	<b>\$1,069</b>	<b>\$964</b>
<b><u>Adjusted EBITDA</u></b>					
Performance Solutions	\$102	\$103	\$116	\$112	\$112
Agricultural Solutions	91	103	81	114	95
<b>Total Adjusted EBITDA</b>	<b>\$193</b>	<b>\$205</b>	<b>\$197</b>	<b>\$226</b>	<b>\$207</b>

Note: Totals may not sum due to rounding



# RECONCILIATION TO CHANGE IN NET WORKING CAPITAL

## Current Platform

(\$ millions)	2016	2017
Change in Accounts Receivable, net	\$(19)	\$(53)
Change in Other Current Assets (Beneficial Interests on Sold Accounts Receivable)	-	(25)
Change in Inventories, net	70	(30)
Change in Accounts Payables	(67)	50
<b>Change in Net Working Capital</b>	<b>\$(16)</b>	<b>\$(58)</b>

## RemainCo / ESI

(\$ millions)	2016	2017
Change in Accounts Receivable, net	\$(40)	\$(31)
Change in Inventories, net	16	(11)
Change in Accounts Payables	(3)	(3)
<b>Change in Net Working Capital</b>	<b>\$(27)</b>	<b>\$(45)</b>

# RECONCILIATION TO NET CAPITAL EXPENDITURES

## Current Platform

(\$ millions)	2016	2017
Reported Capital Expenditures	\$56	\$59
Plus: Investment in Registrations	36	41
Less: Proceeds from Sale of Assets	(21)	(18)
<b>Net Capital Expenditures</b>	<b>\$72</b>	<b>\$82</b>

## RemainCo / ESI

(\$ millions)	2016	2017
Platform Reported Capital Expenditures	\$56	\$59
Less: Agricultural Solutions Capital Expenditures	(23)	(29)
Less: Proceeds from Sale of Assets (excluding Agricultural Solutions)	(9)	(17)
<b>Net Capital Expenditures</b>	<b>\$25</b>	<b>\$14</b>

# ORGANIC SALES GROWTH RECONCILIATION

	LTM Q1-18 Organic Sales Growth				
	Reported Net Sales Growth	Impact of Currency	Metals	Acquisitions	Organic Sales Growth
Performance Solutions	7%	(2)%	—%	—%	4%

	FY 2017 Organic Sales Growth				
	Reported Net Sales Growth	Impact of Currency	Metals	Acquisitions	Organic Sales Growth
Performance Solutions	6%	—%	(1)%	—%	4%

	FY 2016 Organic Sales Growth				
	Reported Net Sales Growth	Impact of Currency	Metals	Acquisitions	Organic Sales Growth
Performance Solutions	121%	6%	(2)%	(123%)	1%

Note: Totals may not sum due to rounding

# NON-GAAP DEFINITIONS

**EBITDA and Adjusted EBITDA:** EBITDA represents earnings before interest, provision for income taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA, excluding the impact of additional items, which are not representative or indicative of the Company's ongoing business as described in the footnotes to the non-GAAP measures reconciliations. Adjusted EBITDA for each segment also includes an allocation of corporate costs, such as compensation expense and professional fees. Management believes adjusted EBITDA and adjusted EBITDA margin provide investors with a more complete understanding of the long-term profitability trends of Platform's business, and facilitate comparisons of its profitability to prior and future periods. However, these measures, which do not consider certain cash requirements, should not be construed as an alternative to net income or cash flow from operations as a measure of profitability or liquidity.

**Comparable Adjusted EBITDA:** Comparable adjusted EBITDA is defined as Adjusted EBITDA adjusted to reflect acquisitions and the related financings as though they had occurred on January 1, 2015 without the impact of purchase accounting. Adjusted EBITDA and comparable adjusted EBITDA are key metrics used by management to measure operating performance and trends. In particular, the exclusion of certain expenses in calculating adjusted EBITDA and comparable adjusted EBITDA facilitates operating performance comparisons on a period-to-period basis. Management believes comparable Adjusted EBITDA provides investors with a more complete understanding of the long-term profitability trends of Platform's business, and facilitates comparisons of its profitability to prior and future periods.

**Constant Currency and Comparable Constant Currency:** Constant currency presentation excludes the impact of fluctuations in foreign currency exchange rates. Constant currency percentages are calculated by converting the current-period local currency financial results into U.S. Dollar using the prior period's exchange rates and comparing these adjusted amounts to our prior period reported results. The difference between actual growth rates and constant currency growth rates represents the impact of foreign currency. The comparable constant currency presentation includes actual results adjusted to reflect acquisitions and related financings as though they had occurred at the beginning of the previous period adjusted for the effects of purchase accounting on actual results. Management believes that these presentations provide a more complete understanding of the Company's operational results and a meaningful comparison of its performance between periods. However, the comparable financial information is provided for informational purposes only and is not necessarily, and should not be assumed to be, an indication of the results that would have been achieved had the Company's acquisitions been completed as of the dates indicated, or that may be achieved in the future.

**Free Cash Flow:** Free cash flow is defined as net cash flows provided by operating activities less net capital expenditures plus proceeds from beneficial interests on sold accounts receivable. Net capital expenditures include capital expenditures plus investments in registrations of products less proceeds from disposal of property, plant and equipment. Adjusted levered free cash flow is defined as net cash flows provided by operating activities (which includes change in net working capital, cash taxes and cash interest) less net capital expenditures plus proceeds from beneficial interests on sold accounts receivable.

**Net Debt to Adjusted EBITDA ratio:** Net Debt to Adjusted EBITDA Ratio is defined as consolidated indebtedness, as defined in Platform's credit agreement, less cash divided by Adjusted EBITDA.

**Organic Sales Growth:** Organic sales growth is defined as net sales excluding the impact of foreign currency translation, changes due to the price of certain metals, and acquisitions and/or divestitures, as applicable. Management believes this non-GAAP financial measure provides investors with a more complete understanding of the underlying net sales trends by providing comparable sales over differing periods on a consistent basis.

For the twelve months ended December 31, 2017, metals pricing benefited Performance Solutions and our consolidated results by \$23.6 million. For the twelve months ended December 31, 2017, acquisitions benefited Performance Solutions and our consolidated results by \$2.8 million. For the twelve months ended December 31, 2016, metals pricing benefited Performance Solutions and our consolidated results by \$13 million. For the twelve months ended March 31, 2018, metals pricing benefited Performance Solutions by \$8 million.

**Pro Forma:** "Pro forma" information excludes the results of the Arysta business by assuming a transaction closing on January 1, 2018 and includes the full benefit of approximately \$25 million of estimated run-rate cost savings expected to be delivered in 2019. This pro forma information, however, should not necessarily be, and should not be assumed to be, an indication of the results that may have been achieved had the Arysta transaction been completed on January 1, 2018, or results that may be achieved in the future. This pro forma information may also not be comparable to the pro forma information required to be provided in connection with the transaction closing.